BOLI AUTOINFLAMATORII

DOI: 10.7241/ourd.2022book.2_7

First Page (Prima pagina)

Bolile auto-inflamatorii (BAI) sunt determinate de anomalii monogenice sau multifactoriale ale imunită?ii înnăscute, care produc episoade recurente de tip inflama?ii multisis-temice, fără factor declan?ant specific [1]. Sistemul imun înnăscut sau nespecific este prima linie de apărare imună, rapidă, nespecifică, fără produc?ia de anticorpi.
BAI au fost descrise în 1999, prototipul fiind febra recurentă ereditară, boală monogenică caracterizată prin modificarea produc?iei de interleukină I (IL-1) [1]. Ulterior conceptul de BAI s-a extins, incluzând alte afec?iuni caracterizate de episoade inflamatorii intermitente, cu febră recurentă inexplicabilă asociată cu manifestări sistemice (în principal cutanate, musculo-scheletice, seroase, oftalmologice). Din punct de vedere genetic spectrul BAI a cuprins bolile monogenice care afectează diferite căi specifice imunită?ii înnăscute: interferon (IFN) sau calea NF-?B, explicând astfel auto-inflama?ia, autoimunitatea ?i deficitul imun [2].
BAI reprezintă boli în care imunitatea înnăscută are rol principal [3].
Manifestările dermatologice din BAI pot apare în copilărie, pot fi caracteristice ?i pot ridica suspiciunea unei afec?iuni de tip auto-inflamator sistemic.


Keywords

  • Bolile auto-inflamatorii; Tumour necrosis factor; PFAPA; DIRA; MAJEED; DITRA; PAPA; SAVI; CANDLE; HA20; PLAID; APLAIDl 

References

1. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133-44.
2. Marino A, Tirelli F, Giani T, et al. Periodic fever syndromes and the autoinflammatory diseases (AIDs). J Transl Autoimmun. 2019;3:100031.
3. Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18:832- 42.
4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al; Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416-25.
5. Soriano A, Soriano M, Espinosa G, et al. Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Front Immunol. 2020;11:865.
6. De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908-19.
7. Fre?mond ML, Rodero MP, Jeremiah N et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in children. JAllergy Clin Immunol. 2016;138:1752-55.
8. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319?25.
9. Dinarello CA. Immunological and Inflammatory Function of the Interleukin-1. Family Annu Rev Immunol. 2009;27:519?50.
10. Da?vila-Seijo P, Herna?ndez-Marti?n A, Torrelo A. Autoinflammatory syndromes for the dermatologist. Clin Dermatol. 2014;32:488?501.
11. Drenth JP, Boom BW, Toonstra J, et al. Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group. Arch Dermatol. 1994;130:59?65.
12. Pettersson T, Kantonen J, Matikainen S, Repo H. Setting up TRAPS. Ann Med. 2012;44:109-18.
13. Lachmann HJ. Clinical immunology review series: An approach to the patient with a periodic fever syndrome. Clin Exp Immunol.2011;165:301-9.

14. Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol. 2008;144:392?402.
15. Toro JR, Aksentijevich I, Hull K, et al. Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol. 2000;136:1487?94.
16. Lamprecht P, Moosig F, Adam-Klages S, et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis. 2004;63:1518?20.
17. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol. 2001;108:615?20.
18. Kolivras A, Theunis A, Ferster A, et al. Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement. J Cutan Pathol. 2011;38:202-8.
19. Kanazawa N. Designation of Autoinflammatory Skin Manifestations With Specific Genetic Backgrounds. Front Immunol. 2020;11:475.
20. Minkis K, Aksentijevich I, Goldbach-Mansky R, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol. 2012;148:747-52.
21. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. NEJM. 2011;365:620-8.
22. Ferguson PJ, Chen S, Tayeh MK, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet. 2005;42:551-7.
23. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc. 1997;72:611-5.
24. Incel Uysal P, Gur Aksoy G, Yalcin B. Clinical findings and outcomes in patients with pyoderma gangrenosum: a single tertiary centre experience. Our Dermatol Online. 2019;10:17-22.
25. Dégboé B, Nouhoumon G, Nguessie C, et al. SAPHO syndrome associated with a digestive disorder in a ten-year-old girl: Diagnostic difficulties. Our Dermatol Online. 2022;13:57-61.
26. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149:762-4.
27. Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409-15.
28. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91-8.
29. Canna SW, Goldbach-Mansky R. New monogenic autoinflammatory diseases?a clinical overview. Semin Immunopathol. 2015;37:387-94.

30. Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. NEJM. 2014;371:507?18.
31. Torrelo A, Patel S, Colmenero I, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol. 2010;62:489-95.
32. Ryme D, BayBay H, Joutei Hassani KT, et al. Strange febrile nodular rash in an infant with muscle atrophy: Candle syndrome to be evoked. Our Dermatol Online. 2022;13:e26.
33. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19-20.
34. Wouters CH, Maes A, Foley KP, et al. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatric Rheumatology. 2014;12:33.
35. Al Aboud K. Mnemonics in dermatopathology. Our Dermatol Online. 2012;3:359-60.

Comments are closed.